| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.35 | 9e-11 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.36 | 2e-07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.33 | 5e-07 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.24 | 9e-07 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.25 | 5e-06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.25 | 1e-05 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.16 | 4e-05 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-05 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |